This week in regulatory: 74 updates, +252% vs last week

The top regulatory developments of the week, ranked by significance

These WHO prequalification actions may indicate a continued tightening of global expectations around diagnostic quality, with Roche’s TB assays reinforcing that internationally recognised performance evidence can materially shape market access and procurement relevance. Sponsors should consider that the consultant roster call suggests WHO is also scaling its review capacity, which could accelerate scrutiny of device and assay dossiers while broadening the pool of technical expectations. Across RA, clinical ops, and QA, professionals should prioritise dossier readiness, data integrity, and cross-functional alignment on analytical and clinical performance claims, since this may determine how credibly a product can move through prequalification pathways and downstream tender environments. Teams should also watch for knock-on effects on comparator selection, evidence packages, and lifecycle change management, because these developments could suggest higher expectations for consistency between submitted data and real-world manufacturing or study execution.